NCT06364228 · Phase 2 · RECRUITING

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

This trial tests whether a daily oxytocin nasal spray, at two different doses versus a placebo, can lower stress and improve quality of life in women who care for a person with dementia. Participants use it for 21 days and have brain scans. It is a Phase 2 trial, testing whether it works and is safe, not yet proven or approved.

You may qualify if

  • Females 50 years of age or older
  • Currently an unpaid family caregiver to an older adult (50 years and older) with dementia for at least five hours a week for at least six months
  • Normal or corrected to normal vision and hearing
  • Mobility to travel to University of Nebraska Medical Center (UNMC) for study procedures including brain imaging
  • Right-handed
  • Capacity to read and write English

You're excluded if

  • Major medical illness that contraindicates oxytocin (OXT) administration (e.g., severe liver disease, seizure disorder, metabolic disorder)
  • History of allergic reaction to oxytocin (OXT) and its nasal spray product
  • History of central nervous system (CNS) disease, including history of seizure, epilepsy, CNS tumor, CNS hemorrhage, or serious CNS infection including meningitis or encephalitis
  • Currently pregnant or planning to become pregnant during the course of the study
  • Metal in the body (i.e., hearing aid, cardiac pacemaker, bone plates, braces, non-removable piercing/implants, etc.), claustrophobia, or any other condition that would preclude magnetic resonance imaging (MRI) scanning
  • Mini-mental status exam score of 25 or lower which suggests possible cognitive issues
  • History of or current neurological disease (e.g., stroke, traumatic brain injury, brain tumor, dementia)
  • History of or current severe psychiatric disease (e.g., schizophrenia, bipolar disorder, autism, severe post-traumatic stress disorder)
  • History of, or current drug or alcohol abuse
  • Currently breastfeeding
  • Current coronavirus disease-19 (COVID-19) illness
  • Left-handed due to brain structural difference between right and left-handed individuals
  • Currently taking antipsychotic medications, selective serotonin reuptake inhibitors (SSRIs) or corticosteroid creams/pills

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-05-05

View full record on ClinicalTrials.gov

All APOE4 clinical trials